Bird & Bird advises Voima Ventures on Hormona’s $6.7 million seed round
Contacts
International law firm Bird & Bird has advised Voima Ventures, as co-lead investor, in connection with Hormona’s $6.7 million seed funding round. This investment will accelerate Hormona's growth, introduce its cutting-edge hormone tests, and establish B2B partnerships. It will also bolster infrastructure, marketing, and sales efforts.
Voima Ventures is a deep tech venture capital firm that invests in early-stage companies with strong scientific foundations, focusing on biotechnology, software, AI, and other advanced technologies. Based in Finland, they aim to solve major global problems by combining science, entrepreneurship, and value-adding capital.
Hormona is a UK and Swedish based health tech company focused on revolutionising hormone health management through AI powered personalised insights and data-driven solutions. Their platform aims to empower individuals by providing tools for tracking and understanding hormonal changes, ultimately improving overall well-being.
The Bird & Bird corporate team was led by Adam Meisels (Partner, London) and William Alms (Associate, London) with support from Martin Folke (Partner, Stockholm) and Erik Holmgren (Counsel, Stockholm).
Adam Meisels commented on the transaction: “We are delighted to have worked alongside Voima in this significant investment. This investment is one of many that demonstrates Bird & Bird's commercial experience within the Life Sciences & Healthcare sectors and our expertise in collaborating on investments into innovative companies like Hormona, which are at the forefront of health tech. We look forward to seeing the positive impact this investment will have.”